By Will FeuerBiogen said the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's Tecfidera drug, a treatment for relapsing multiple sclerosis. Drugmakers Accord, Mylan, Neuraxpharm, Polpharma and Teva held the authorizations for the generic versions, Biogen said.

Source: Wall Street Journal December 19, 2023 12:44 UTC